基于智能手机应用程序中1000万用户自我报告记录对25种急性偏头痛药物进行同步比较
该研究回顾性分析了2014年6月30日至2020年7月2日期间从电子日记智能手机应用程序中提取的10,842,795条偏头痛发作记录,最终分析纳入278,006名用户的3,119,517次偏头痛发作中的4,777,524对药物-结局数据,采用两级嵌套logistic回归模型比较25种急性偏头痛药物的疗效比值比(OR)。结果显示,曲普坦类(平均OR 4.8)、麦角类(平均OR 3.02)和止吐药(平均OR 2.67)是疗效最高的前3类药物,优于布洛芬参照;阿司匹林除外的24种药物OR均达到统计学显著性(p < 0.0001),模型曲线下面积(AUC)为0.849。结论认为曲普坦类、麦角类和止吐药是最有效的药物类别,与指南推荐一致。
要点
- 曲普坦类(平均OR 4.8)、麦角类(平均OR 3.02)和止吐药(平均OR 2.67)是疗效最高的前3类药物。
- 单个药物中OR最高的是依来曲普坦(OR 6.1,95%CI 6.0-6.3)、佐米曲普坦(OR 5.7,95%CI 5.6-5.8)和舒马曲普坦(OR 5.2,95%CI 5.2-5.3)。
- 对乙酰氨基酚、非甾体抗炎药(NSAIDs)、复方镇痛药和阿片类药物的OR大多接近或小于1,提示与布洛芬相比疗效相似或更低。
核心结论
- 曲普坦类、麦角类和止吐药是最有效的急性偏头痛药物类别,与指南推荐一致,可提供普适性见解以补充临床实践。
研究设计与样本
- 回顾性分析2014年6月30日至2020年7月2日期间从电子日记智能手机应用程序中提取的10,842,795条偏头痛发作记录。
- 最终分析纳入278,006名用户的3,119,517次偏头痛发作中的4,777,524对药物-结局数据,分析25种急性药物(7类:对乙酰氨基酚、非甾体抗炎药、曲普坦类、复方镇痛药、麦角类、止吐药和阿片类药物),未包括Gepants和ditan。
- 采用两级嵌套logistic回归模型分析各药物治疗有效性的比值比(OR),调整合并用药和同一用户内的协方差;并对美国、英国和加拿大用户进行亚组分析。
主要发现
- 曲普坦类平均OR 4.8、麦角类平均OR 3.02、止吐药平均OR 2.67为疗效最高的前3类药物,其次为阿片类平均OR 2.49、非甾体抗炎药(布洛芬除外)平均OR 1.94、复方镇痛药(对乙酰氨基酚/乙酰水杨酸/咖啡因)OR 1.69(95%CI 1.67-1.71)、其他药物OR 1.49(95%CI 1.47-1.50)、对乙酰氨基酚OR 0.83(95%CI 0.83-0.84),以布洛芬为参照。
- 单个药物中OR最高的是依来曲普坦(OR 6.1,95%CI 6.0-6.3)、佐米曲普坦(OR 5.7,95%CI 5.6-5.8)和舒马曲普坦(OR 5.2,95%CI 5.2-5.3)。
- 对乙酰氨基酚、非甾体抗炎药、复方镇痛药和阿片类药物的OR大多接近或小于1,提示与布洛芬相比报告的有效性相似或更低。
- 除乙酰水杨酸外,24种药物的OR均达到统计学显著性(p < 0.0001),嵌套logistic回归模型AUC为0.849。
- 国家特异性亚组分析显示各药物OR和AUC相似(美国0.849、英国0.864、加拿大0.842),表明分析具有稳健性。
关键数值与推荐
- 以布洛芬为参照,曲普坦类平均OR 4.8、麦角类平均OR 3.02、止吐药平均OR 2.67、阿片类平均OR 2.49、非甾体抗炎药(布洛芬除外)平均OR 1.94、复方镇痛药OR 1.69(95%CI 1.67-1.71)、其他药物OR 1.49(95%CI 1.47-1.50)、对乙酰氨基酚OR 0.83(95%CI 0.83-0.84)。
- 依来曲普坦OR 6.1(95%CI 6.0-6.3)、佐米曲普坦OR 5.7(95%CI 5.6-5.8)、舒马曲普坦OR 5.2(95%CI 5.2-5.3)。
- 除乙酰水杨酸外,24种药物的OR均达到统计学显著性(p < 0.0001),模型AUC为0.849。
- 亚组AUC:美国0.849、英国0.864、加拿大0.842。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Many acute treatment options exist for migraine. However, large-scale, head-to-head comparisons of treatment effectiveness from real-world patient experience reports are lacking. METHODS: This is a retrospective analysis of 10,842,795 migraine attack records extracted from an e-diary smartphone application between June 30, 2014, and July 2, 2020. We analyzed 25 acute medications among 7 classes-acetaminophen, nonsteroid anti-inflammatory drugs (NSAIDs), triptans, combination analgesics, ergots, antiemetics, and opioids. Gepants and ditan were not included in this analysis. Different doses and formulations of each medication, according to the generic names, were combined in this analysis. We used a 2-level nested logistic regression model to analyze the odds ratio (OR) of treatment effectiveness of each medication by adjusting concurrent medications and the covariance within the same user. Subgroup analyses were conducted for users in the United States, the United Kingdom, and Canada. RESULTS: Our final analysis included 4,777,524 medication-outcome pairs from 3,119,517 migraine attacks among 278,006 users. Triptans (mean OR 4.8), ergots (mean OR 3.02), and antiemetics (mean OR 2.67) were the top 3 classes of medications with the highest effectiveness, followed by opioids (mean OR 2.49), NSAIDs (other than ibuprofen, mean OR 1.94), combination analgesics (acetaminophen/acetylsalicylic acid/caffeine) (OR 1.69, 95% CI 1.67-1.71), others (OR 1.49, 95% CI 1.47-1.50), and acetaminophen (OR 0.83, 95% CI 0.83-0.84), using ibuprofen as the reference. Individual medications with the highest ORs were eletriptan (OR 6.1, 95% CI 6.0-6.3), zolmitriptan (OR 5.7, 95% CI 5.6-5.8), and sumatriptan (OR 5.2, 95% CI 5.2-5.3). The ORs of acetaminophen, NSAIDS, combination analgesics, and opioids were mostly around or less than 1, suggesting similar or lower reported effectiveness compared with ibuprofen. The ORs for 24 medications, except that of acetylsalicylic acid, achieved statistical significance with p < 0.0001, and our nested logistic regression model achieved an area under the curve (AUC) of 0.849. Country-specific subgroup analyses revealed similar ORs of each medication and AUC (United States 0.849, United Kingdom 0.864, and Canada 0.842), demonstrating the robustness of our analysis. DISCUSSION: Using a big data approach, we analyzed patient-generated real-time records of 10 million migraine attacks and conducted simultaneous head-to-head comparisons of 25 acute migraine medications. Our findings that triptans, ergots, and antiemetics are the most effective classes of medications align with the guideline recommendations and offer generalizable insights to complement clinical practice. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with migraine, selected acute medications (e.g., triptans, ergots, antiemetics) are associated with higher odds of user-rated positive response than ibuprofen.
引用
- Chiang CC, Fang X, Horvath Z, et al. Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users' Self-Reported Records From a Smartphone Application. Neurology. 2023. PMID: 38030397. doi:10.1212/WNL.0000000000207964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。